메뉴 건너뛰기

추천
검색
질문

논문 기본 정보

자료유형
학술저널
저자정보
(Yonsei University College of Medicine) (Yonsei University College of Medicine) (Yonsei University College of Medicine) (Yonsei University College of Medicine) (Yonsei University College of Medicine) (Yonsei University College of Medicine) (Yonsei University College of Medicine) (Yonsei University College of Medicine) (Yonsei University College of Medicine)
저널정보
한국간담췌외과학회 Annals of Hepato-Biliary-Pancreatic Surgery 한국간담췌외과학회지 제26권 특별호
발행연도
수록면
280 - 280 (1page)

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
이 논문의 연구방법이 궁금하신가요?
🏆
연구결과
이 논문의 연구결과가 궁금하신가요?
AI에게 요청하기
추천
검색
질문

초록· 키워드

Pancreatic cancer is the fourth leading cause of cancer death and the 5-year survival rate is less than 8% due to late diagnosis, frequent metastases, and limited treatment options. Currently, gemcitabine is the standard first-line chemotherapy for patients with pancreatic cancer, but still does not contribute to improving overall survival. Therefore, it is necessary to identify new chemotherapeutic agents or therapeutic strategies to enhance the effect of tumor susceptibility to gemcitabine and reduce tumor growth. To investigate the effect of ivermectin, gemcitabine, and ivermectin-gemcitabine combination treatment on human pancreatic cancer cells. We performed WST assay for 72 hours to measure the cell viability. We evaluated cell cycle arrest and apoptosis using FACS analysis. Also, we confirmed ROS levels to characterize the mechanism of apoptosis using redox sensitive dye DCFDA and evaluated MMP by JC-10 staining. Moreover, we checked OCR level using Seahorse assay. With pancreatic cancer xenograft model, we confirmed that combina ... 전체 초록 보기
상세정보 수정요청해당 페이지 내 제목·저자·목차·페이지
정보가 잘못된 경우 알려주세요!

목차

등록된 정보가 없습니다.

참고문헌

참고문헌 신청

최근 본 자료

전체보기